ArticleViruses2021
Modeling within-Host SARS-CoV-2 Infection Dynamics and Potential Treatments.
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 79 citations in OpenAlex.
- Ordinary differential equation models of SARS-CoV-2 replication dynamics and antiviral drug efficacies.Npj viruses · 2026Review
- Modelling and investigating memory immune responses in infectious disease. Application to influenza a virus and sars-cov-2 reinfections.Infectious Disease Modelling · 2025Article
- Differences in virus and immune dynamics for SARS-CoV-2 Delta and Omicron infections by age and vaccination histories.BMC infectious diseases · 2024Article
- How robust are estimates of key parameters in standard viral dynamic models?PLoS computational biology · 2024Article
- Vaccine and antiviral drug promise for preventing post-acute sequelae of COVID-19, and their combination for its treatment.Frontiers in immunology · 2024Article
- Stability of a delayed SARS-CoV-2 reactivation model with logistic growth and adaptive immune response.Physica A · 2023Article
- A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions.NPJ systems biology and applications · 2023Article
- The race to understand immunopathology in COVID-19: Perspectives on the impact of quantitative approaches to understand within-host interactions.Immunoinformatics (Amsterdam, Netherlands) · 2023Review
- A mathematical model of the within-host kinetics of SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination.Journal of theoretical biology · 2023Article
- Machine Learning and COVID-19: Lessons from SARS-CoV-2.Advances in experimental medicine and biology · 2023Article
- Global Dynamics of SARS-CoV-2 Infection with Antibody Response and the Impact of Impulsive Drug Therapy.Vaccines · 2022Article
- Identifiability of parameters in mathematical models of SARS-CoV-2 infections in humans.Scientific reports · 2022Article
- A simple model of COVID-19 explains disease severity and the effect of treatments.Scientific reports · 2022Article
- Modeling within-host and aerosol dynamics of SARS-CoV-2: The relationship with infectiousness.PLoS computational biology · 2022Article
- A multicompartment mathematical model based on host immunity for dissecting COVID-19 heterogeneity.Heliyon · 2022Article
- Understanding the dynamics of SARS-CoV-2 variants of concern in Ontario, Canada: a modeling study.Scientific reports · 2022Article
- The mixed blessing of AMPK signaling in Cancer treatments.BMC cancer · 2022Article
- Macrophage Boolean networks in the time of SARS-CoV-2.Frontiers in immunology · 2022Article
- Computational simulations to dissect the cell immune response dynamics for severe and critical cases of SARS-CoV-2 infection.Computer methods and programs in biomedicine · 2021Article
- Estimation of viral kinetics model parameters in young and aged SARS-CoV-2 infected macaques.Royal Society open science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The goal of this study was to develop a mathematical model to simulate the actions of drugs that target SARS-CoV-2 virus infection. To accomplish that goal, we have developed a mathematical model that describes the control of a SARS-CoV-2 infection by the innate and adaptive immune components. Invasion of the virus triggers the innate immunity, whereby interferon renders some of the target cells resistant to infection, and infected cells are removed by effector cells. The adaptive immune response is represented by plasma cells and virus-specific antibodies. The model is parameterized and then validated against viral load measurements collected in COVID-19 patients. We apply the model to simulate three potential anti-SARS-CoV-2 therapies: (1) Remdesivir, a repurposed drug that has been shown to inhibit the transcription of SARS-CoV-2, (2) an alternative (hypothetical) therapy that inhibits the virus' entry into host cells, and (3) convalescent plasma transfusion therapy. Simulation results point to the importance of early intervention, i.e., for any of the three therapies to be effective, it must be administered sufficiently early, not more than a day or two after the onset of symptoms. The model can serve as a key component in integrative platforms for rapid in silico testing of potential COVID-19 therapies and vaccines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.